The Middle Kingdom joins the growing list of jurisdictions to greenlight the blockbuster laser vision correction tech.
ZEISS Medical Technology (a subsidiary of Carl Zeiss Meditec AG; Jena, Germany) announced on Wednesday that it has received approval from China’s National Medical Products Administration (NMPA) for the VISUMAX 800 with SMILE pro software. The femtosecond laser system is now available in China for the surgical treatment of nearsightedness, with or without astigmatism.
The approval comes as more than 10 million eyes worldwide have already been treated with ZEISS SMILE and SMILE pro, reflecting strong global adoption in Asia, Europe and the United States.
“With the growing interest in laser vision correction in China, the market needs innovative technology that enhances surgical outcomes, safety and efficiency to benefit both surgeons and their patients,” said Maximilian Foerst, head of ZEISS Greater China.
Enhanced surgical precision and efficiency
According to the company, the ZEISS VISUMAX 800 with SMILE pro software introduces several key advancements designed to improve surgical precision and efficiency.
The system’s faster laser pulse repetition rate of 2 MHz enables lenticule creation in less than 10 seconds, significantly reducing procedure time. A shorter treatment duration can help minimize stress for both surgeons and patients, enhancing the overall surgical experience.
Additionally, the system now offers greater flexibility, adapting to different clinical environments with its smaller footprint and compatibility with a variety of patient beds.
Key features for surgeons in China
With the introduction of the ZEISS VISUMAX 800 with SMILE pro software, refractive surgeons in China will have access to:
- CentraLign: a computer-controlled function that simplifies centration for improved precision.
- OcuLign cyclotorsion adjustment: helps counteract cyclotorsion movements that may occur during surgery.
- VISULYZE user nomograms: collects and analyzes patient data, offering surgeons detailed nomograms and greater control over each procedure.
“This next-generation femtosecond laser system creates data-driven insights to help surgeons better manage treatment paths for patients while supporting each surgeon’s unique practice requirements for greater workflow efficiency and performance,” said Magnus Reibenspiess, head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology.
For more, see the full press release on ZEISS’ website.
